Orion Portfolio Solutions LLC Sells 14,132 Shares of Hologic, Inc. (NASDAQ:HOLX)

Orion Portfolio Solutions LLC reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 21.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 51,680 shares of the medical equipment provider’s stock after selling 14,132 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Hologic were worth $3,726,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HOLX. Nomura Asset Management Co. Ltd. grew its stake in Hologic by 1.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 121,417 shares of the medical equipment provider’s stock worth $8,753,000 after purchasing an additional 1,771 shares in the last quarter. Triodos Investment Management BV increased its stake in shares of Hologic by 19.1% during the fourth quarter. Triodos Investment Management BV now owns 42,000 shares of the medical equipment provider’s stock valued at $3,028,000 after buying an additional 6,750 shares during the period. Norges Bank purchased a new position in shares of Hologic during the fourth quarter valued at $133,414,000. Caisse Des Depots ET Consignations bought a new stake in shares of Hologic in the fourth quarter valued at about $1,473,000. Finally, NEOS Investment Management LLC lifted its stake in Hologic by 28.5% in the fourth quarter. NEOS Investment Management LLC now owns 11,183 shares of the medical equipment provider’s stock worth $806,000 after acquiring an additional 2,483 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Down 1.6 %

Shares of Hologic stock opened at $61.32 on Monday. The firm’s 50 day simple moving average is $65.24 and its two-hundred day simple moving average is $73.24. The firm has a market capitalization of $13.76 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12-month low of $60.34 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on HOLX. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Evercore ISI lowered their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Citigroup dropped their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, Morgan Stanley dropped their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.